TURBO UNLIMITED SHORT- OPTIONSSCHEIN OHNE STOPP-LOSS-LEVEL - ELI LILLY & CO TURBO UNLIMITED SHORT- OPTIONSSCHEIN OHNE STOPP-LOSS-LEVEL - ELI LILLY & CO Share Price
Certificat
DE000SU8MAF0
| Market Closed - Boerse Frankfurt Warrants 20:47:07 10/06/2024 BST | ||
| 10.25 EUR | -8.89% |
|
| Current month | -27.48% | ||
| 1 month | -46.85% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ELI LILLY AND COMPANY
Latest news about ELI LILLY AND COMPANY
More news
| Date | Price | Change |
|---|---|---|
| 10/06/24 | 10.45 | -7.11% |
| 07/06/24 | 11.25 | -10.36% |
| 06/06/24 | 12.55 | -1.65% |
| 05/06/24 | 12.76 | -0.93% |
| 04/06/24 | 12.88 | -2.35% |
Real-time Boerse Frankfurt Warrants
Last update June 10, 2024 at 08:47 pm
More quotesStatic data
| Product type | Knock-Out without Stop Loss |
|---|---|
| Buy / Sell | PUT |
| Underlying | ELI LILLY AND COMPANY |
| Issuer | 
Société Générale
|
| WKN | SU8MAF |
| ISIN | DE000SU8MAF0 |
| Date issued | 08/02/2024 |
| Strike | 970.7 $ |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 21.92 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 23.56 € |
|---|---|
| Lowest since issue | 10.25 € |
Company Profile
Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows:
- endocrinology (57.7%): products for treating osteoporosis, diabetes, and growth problems;
- oncology (19.5%);
- immunology diseases (11.1%);
- neurology (8.4%): primarily drugs used in treating depression and schizophrenia;
- other (3.3%).
Net sales are distributed geographically as follows: the United States (63.9%), Europe (18.1%), Japan (4.9%), China (4.5%) and other (8.6%).
Sector
-
Consensus: Eli Lilly and Company
Sell
Buy
Mean consensus
BUY
Number of Analysts
28
Last Close Price
865
USD
Average target price
855.2
USD
Spread / Average Target
-1.14%
- Stock Market
- Certificates
- Certificat